Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

2000688 citationsJournal Article

Authors

In this re-treatment population, safety and efficacy were not apparently different from those after initial rituximab exposure.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 18, Issue 17, pp. 3135-3143

Field-Weighted Citation Impact: 26.42